Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Ibio ( (IBIO) ).
On January 8, 2026, iBio, Inc. entered into a securities purchase agreement with existing, healthcare-focused institutional investors for an at-the-market private placement of 1,408,481 common shares and pre-funded warrants to purchase up to 9,653,257 additional shares, at a price of $2.35 per share (or $2.349 per pre-funded warrant). The transaction, led by Frazier Life Sciences with Leerink Partners as lead placement agent and LifeSci Capital and Oppenheimer & Co. as co-placement agents, is expected to close on or about January 13, 2026 and generate approximately $26 million in gross proceeds. The funding is earmarked to advance iBio’s preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and its myostatin and activin A bispecific programs, as well as other preclinical assets and general corporate purposes, and is expected to extend the company’s cash runway into calendar 2028; the deal also includes customary beneficial-ownership caps on warrant exercises and registration rights obligating iBio to register the resale of the newly issued securities.
The most recent analyst rating on (IBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.
Spark’s Take on IBIO Stock
According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, large ongoing losses, and significant cash burn), partially offset by supportive technical trend/momentum and positive corporate updates (Nasdaq compliance and encouraging preclinical data). Valuation remains challenged due to losses and no dividend support.
To see Spark’s full report on IBIO stock, click here.
More about Ibio
iBio, Inc. (Nasdaq: IBIO) is a cutting-edge biotechnology company that leverages artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals targeting cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. By combining proprietary 3D modeling with innovative drug discovery platforms, the company is building a pipeline of precision antibody therapies aimed at significant unmet medical needs.
Average Trading Volume: 7,921,675
Technical Sentiment Signal: Sell
Current Market Cap: $52.85M
Find detailed analytics on IBIO stock on TipRanks’ Stock Analysis page.